1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Alizyme's Colal-Pred stumbles in Phase III

 
• By Tom Moberly

Alizyme Therapeutics' investigational ulcerative colitis treatment Colal-Pred has failed to meet one of its primary endpoints in a pivotal Phase III trial. Colal-Pred, a colonic-release formulation of prednisolone, showed inferior efficacy to conventional prednisolone in the trial.

Alizyme Therapeutics' investigational ulcerative colitis treatment Colal-Pred has failed to meet one of its primary endpoints in a pivotal Phase III trial. Colal-Pred, a colonic-release formulation of prednisolone, showed inferior efficacy to conventional prednisolone in the trial.

Shares in the UK-listed biotech company fell by 50% to 7.76p on the London Stock Exchange on July 24th, following...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapeutic Category

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By Kevin Grogan

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: AbbVie’s big autoimmune CAR-T play; In Vivo CAR-T interest grows; China deal perspectives from BIO; global pharma interest in Korea undeterred; and a look at the biggest drug sales disappointments.

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By Kevin Grogan

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.